fluoxetine has been researched along with Clinically Isolated CNS Demyelinating Syndrome in 3 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluoxetine treatment in the luxol fast blue (LFB) staining of the corpus callosum has been led to an increase in myelination capacity in all doses and times." | 1.72 | Effect of fluoxetine treatment on neurotoxicity induced by lysolecithin in male rats. ( Ahmadi, M; Alipour, M; Chehelcheraghi, F; Gholami, E; Gholami, MR; Khaksarian, M; Rezaian, J; Tavakoli, A, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Gholami, E | 1 |
| Gholami, MR | 1 |
| Tavakoli, A | 1 |
| Ahmadi, M | 1 |
| Rezaian, J | 1 |
| Alipour, M | 1 |
| Chehelcheraghi, F | 1 |
| Khaksarian, M | 1 |
| Grech, LB | 1 |
| Butler, E | 1 |
| Stuckey, S | 1 |
| Hester, R | 1 |
| Mostert, JP | 1 |
| De Keyser, J | 1 |
3 other studies available for fluoxetine and Clinically Isolated CNS Demyelinating Syndrome
| Article | Year |
|---|---|
Effect of fluoxetine treatment on neurotoxicity induced by lysolecithin in male rats.
Topics: Animals; Brain-Derived Neurotrophic Factor; Corpus Callosum; Demyelinating Diseases; Disease Models, | 2022 |
Letter to the editor: FLOUX-PMS study sample considerations.
Topics: Demyelinating Diseases; Fluoxetine; Humans; Multiple Sclerosis | 2019 |
Response to Grech et al.: FLOUX-PMS study sample considerations.
Topics: Demyelinating Diseases; Fluoxetine; Humans; Multiple Sclerosis | 2019 |